Trial · NCT01713582
Adverse events8,505
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 8,505
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Anaemia | Blood and lymphatic system disorders | AL 10 mg QD 14-21 | 2 | 3 | |
| other | Anaemia | Blood and lymphatic system disorders | AL 20 mg QD 14-21 | 2 | 3 | |
| other | Anaemia | Blood and lymphatic system disorders | AL 40 mg QD 14-21 | 3 | 4 | |
| other | Anaemia | Blood and lymphatic system disorders | AL 20 mg BID 21-21 | 1 | 3 | |
| other | Anaemia | Blood and lymphatic system disorders | AL 80 mg QD 14-21 | 4 | 4 | |
| other | Anaemia | Blood and lymphatic system disorders | AL 40 mg BID 14-21 | 7 | 8 | |
| other | Anaemia | Blood and lymphatic system disorders | AL 120 mg QD 14-21 | 5 | 7 | |
| other | Anaemia | Blood and lymphatic system disorders | AL 120 mg QD 21-21 | 5 | 6 | |
| other | Anaemia | Blood and lymphatic system disorders | AL 160 mg QD 14-21 | 3 | 6 | |
| other | Anaemia | Blood and lymphatic system disorders | AML de Novo 80 mg QD 14-21 | 9 | 18 | |
| other | Anaemia | Blood and lymphatic system disorders | AML/MDS 80 mg QD 14-21 | 7 | 16 | |
| other | Anaemia | Blood and lymphatic system disorders | OHM 10 mg QD 21-21 | 1 | 5 | |
| other | Anaemia | Blood and lymphatic system disorders | OHM 20 mg QD 21-21 | 0 | 3 | |
| other | Anaemia | Blood and lymphatic system disorders | OHM 40 mg QD 21-21 | 1 | 4 | |
| other | Anaemia | Blood and lymphatic system disorders | OHM 40 mg BID 21-21 | 3 | 6 | |
| other | Anaemia | Blood and lymphatic system disorders | OHM 120 mg QD 21-21 | 1 | 7 | |
| other | Anaemia | Blood and lymphatic system disorders | OHM 120 mg QD 14-21 | 1 | 3 | |
| other | Anaemia | Blood and lymphatic system disorders | OHM 120 mg QD 5-7 | 3 | 5 | |
| other | Anaemia | Blood and lymphatic system disorders | OHM 120 mg QD 7-21 | 0 | 5 | |
| other | Anaemia | Blood and lymphatic system disorders | OHM/DLBCL 80 mg QD 14-21 | 1 | 15 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01713582/events